Takeoka Hiroaki, Furusyo Norihiro, Toyoda Kazuhiro, Murata Masayuki, Sagara Yasuko, Kashiwagi Seizaburo, Hayashi Jun
Department of Environmental Medicine and Infectious Diseases, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Am J Trop Med Hyg. 2007 Jul;77(1):192-6.
Human T-lymphotropic virus type 1 (HTLV-1) infection is known to affect hepatitis C virus (HCV) clearance and to accelerate the development of hepatocellular carcinoma in HCV-infected patients. In this study, we found the prevalence and titer of an antibody recognizing the central region of the HTLV-1 Gp46 protein to be associated with the severity of chronic liver disease. The antibody prevalence was significantly correlated with the stage of chronic liver disease (P < 0.0001): 3 (14.3%) of 21 patients with minimal-mild chronic hepatitis, 12 (24%) of 50 with moderate-severe chronic hepatitis, 7 (87.5%) of 8 with liver cirrhosis, and 13 (100%) of 13 with hepatocellular carcinoma. These results indicate that the antibody may be a useful marker of the deterioration of liver disease in patients co-infected with HCV and HTLV-1. This antibody may be useful for the diagnosis of liver diseases and the development of more effective treatments.
已知人类嗜T淋巴细胞病毒1型（HTLV-1）感染会影响丙型肝炎病毒（HCV）清除，并加速HCV感染患者肝细胞癌的发展。在本研究中，我们发现识别HTLV-1 Gp46蛋白中央区域的抗体的流行率和滴度与慢性肝病的严重程度相关。抗体流行率与慢性肝病分期显著相关（P < 0.0001）：21例轻度慢性肝炎患者中有3例（14.3%），50例中度至重度慢性肝炎患者中有12例（24%），8例肝硬化患者中有7例（87.5%），13例肝细胞癌患者中有13例（100%）。这些结果表明，该抗体可能是HCV和HTLV-1合并感染患者肝病恶化的有用标志物。这种抗体可能有助于肝病的诊断和更有效治疗方法的开发。
